Skip to main content

Table 3 Multivariate analysis of factors determining outcomes at 2 years

From: Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT

N = 2156 RI NRM LFS OS GRFS Acute GVHD II-IV Acute GVHD III-IV Chronic GVHD Extensive cGVHD
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
MRD pos vs neg 1.51 (1.26–1.80) < 0.001 0.99 (0.80–1.23) 0.928 1.26 (1.10–1.44) 0.001 1.19 (1.02–1.39) 0.028 1.25 (1.10–1.41) < 0.001 1.12 (0.96–1.32) 0.161 1.09 (0.80–1.48) 0.585 1.00 (0.85–1.18) 0.996 0.99 (0.79–1.24) 0.949
Ph neg B-ALL 1 1 1 1 1 1 1 1 1
Ph pos B-ALL 0.94 (0.75–1.18) 0.609 1.43 (1.07–1.91) 0.015 1.12 (0.94–1.33) 0.198 0.94 (0.72–1.14) 0.531 1.02 (0.87–1.19) 0.818 0.96 (0.79–1.17) 0.663 0.87 (0.61–1.25) 0.456 0.95 (0.78–1.16) 0.637 1.08 (0.82–1.42) 0.578
T-ALL 1.11 (0.86–1.43) 0.445 1.11 (0.78–1.58) 0.554 1.13 (0.92–1.39) 0.246 1.06 (0.85–1.33) 0.611 1.03 (0.86–1.25) 0.720 1.10 (0.87–1.39) 0.429 0.84 (0.54–1.30) 0.440 0.84 (0.66–1.06) 0.138 1.01 (0.73–1.41) 0.938
Age (per 10 years) 1.03 (0.96–1.11) 0.369 1.32 (1.22–1.42) < 0.001 1.15 (1.09–1.21) < 0.001 1.21 (1.14–1.28) < 0.001 1.12 (1.06–1.18) < 0.001 1.08 (1.01–1.15) 0.019 1.09 (0.97–1.22) 0.170 1.07 (1.01–1.14) 0.025 1.06 (0.97–1.15) 0.218
Year of HCT 0.97 (0.95–0.99) 0.042 0.97 (0.94–1.00) 0.053 0.97 (0.95–0.99) 0.005 0.98 (0.95–0.10) 0.030 0.99 (0.97–1.00) 0.096 0.98 (0.96–0.10) 0.032 0.97 (0.93–1.01) 0.173 0.97 (0.94–0.99) 0.002 1.01 (0.98–1.04) 0.628
CR2 vs CR1 2.29 (1.83–2.88) < 0.001 1.63 (1.2–2.23) 0.002 2.02 (1.68–2.42) < 0.001 2.11 (1.72–2.59) < 0.001 1.70 (1.43–2.03) < 0.001 1.21 (0.97–1.52) 0.096 1.58 (1.06–2.36) 0.025 1.07 (0.82–1.40) 0.604 1.19 (0.82–1.73) 0.358
KPS > =90% 1.09 (0.88–1.35) 0.418 1.14 (0.89–1.47) 0.297 1.12 (0.95–1.31) 0.173 1.01 (0.85–1.21) 0.896 1.03 (0.90–1.19) 0.648 0.98 (0.82–1.18) 0.839 0.97 (0.69–1.36) 0.841 1.02 (0.85–1.22) 0.826 1.08 (0.84–1.39) 0.543
UD 10/10 0.66 (0.52–0.83) < 0.001 1.91 (1.45–2.51) < 0.001 1.02 (0.86–1.22) 0.793 1.24 (1.01–1.51) 0.038 1.14 (0.97–1.34) 0.125 1.66 (1.35–2.05) < 0.001 2.02 (1.38–2.95) < 0.001 1.39 (1.14–1.70) 0.001 1.26 (0.96–1.66) 0.099
UD 9/10 0.57 (0.42–0.81) 0.001 2.10 (1.49–2.98) < 0.001 1.01 (0.80–1.27) 0.942 1.31 (1.01–1.69) 0.043 1.02 (0.82–1.26) 0.876 1.73 (1.33–2.26) < 0.001 1.75 (1.04–2.94) 0.035 1.32 (1.01–1.73) 0.042 1.07 (0.73–1.59) 0.716
Blood vs BM 0.90 (0.73–1.10) 0.288 1.07 (0.83–1.38) 0.607 0.95 (0.82–1.11) 0.534 0.39 (0.77–1.12) 0.432 1.17 (1.01–1.36) 0.043 1.08 (0.88–1.33) 0.450 1.14 (0.79–1.65) 0.496 1.44 (1.18–1.76) < 0.001 1.83 (1.37–2.45) < 0.001
Female vs male 0.80 (0.67–0.96) 0.018 0.93 (0.75–1.16) 0.531 0.86 (0.75–0.99) 0.031 0.86 (0.74–1.01) 0.062 0.88 (0.77–0.99) 0.039 0.94 (0.80–1.11) 0.466 0.73 (0.53–0.10) 0.047 0.92 (0.79–1.08) 0.294 0.91 (0.73–1.14) 0.411
Donor fem vs male 0.66 (0.55–0.80) < 0.001 1.29 (1.05–1.60) 0.018 0.89 (0.77–1.02) 0.098 0.97 (0.83–1.13) 0.671 0.96 (0.85–1.09) 0.519 1.11 (0.94–1.30) 0.209 1.00 (0.73–1.37) 0.986 1.33 (1.13–1.55) < 0.001 1.23 (0.99–1.53) 0.0593
Pt CMV pos vs neg 0.93 (0.76–1.13) 0.447 1.23 (0.98–1.56) 0.081 1.06 (0.91–1.23) 0.462 1.24 (1.05–1.47) 0.014 1.02 (0.89–1.17) 0.784 0.96 (0.80–1.13) 0.603 1.01 (0.73–1.41) 0.943 0.10 (0.84–1.19) 0.972 1.04 (0.81–1.32) 0.780
Dr CMV pos vs neg 1.12 (0.92–1.36) 0.276 0.89 (0.71–1.11) 0.300 0.99 (0.86–1.15) 0.931 0.95 (0.81–1.12) 0.548 1.07 (0.94–1.23) 0.315 1.08 (0.91–1.28) 0.364 1.11 (0.80–1.54) 0.523 1.18 (1.00–1.40) 0.0567 1.30 (1.02–1.65) 0.036
TBI vs chemo 0.60 (0.49–0.74) < 0.001 0.87 (0.68–1.12) 0.292 0.70 (0.60–0.82) < 0.001 0.75 (0.62–0.90) 0.002 0.88 (0.76–1.03) 0.104 1.18 (0.95–1.46) 0.126 1.02 (0.69–1.51) 0.922 1.23 (0.99–1.52) 0.0647 1.27 (0.93–1.75) 0.131
In vivo TCD vs no TCD 1.22 (0.97–1.53) 0.090 0.68 (0.52–0.88) 0.004 0.94 (0.79–1.12) 0.494 0.84 (0.69–1.02) 0.077 0.75 (0.64–0.88) < 0.001 0.72 (0.59–0.89) 0.002 0.51 (0.33–0.75) < 0.001 0.58 (0.47–0.71) < 0.001 0.48 (0.36–0.64) < 0.001
Center (frailty) 0.314 0.17 0.295 0.015 0.019 < 0.001 < 0.001 0.028 0.004
  1. Abbreviations: BM bone marrow, CR complete remission, CMV cytomegalovirus, dr donor, GVHD graft-versus-host disease, GRFS GVHD-free and relapse-free survival, HCT hematopoietic cell transplantation, KPS Karnofsky performance score, LFS leukemia-free survival, MRD measurable residual disease, NRM non-relapse mortality, OS overall survival, Ph Philadelphia chromosome/BCR-ABL gene rearrangement, pt patient, RI relapse incidence, TCD T cell depletion, UD unrelated donor